Kei Pharma<4896.T>
The stock has reached its limit-up buy demand. The company, along with Keio University School of Medicine, announced new research results last weekend on the 21st regarding regenerative medicine targeting subacute spinal cord injuries, which is one of the development pipelines (new drug candidates) for regenerative medicine. In clinical research using iPS cell-derived neural precursor cells, improvements were observed in two out of four patients.
Syphus<4892.T>
The Tokyo Stock Exchange lifted the margin trading measures for transactions of the company's stock starting from the trades on the 24th. The Tokyo Stock Exchange had implemented a measure to...
Comment(0)
Reason For Report